Results 81 to 90 of about 9,051 (207)

Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use

, 2017
Background: After stopping serotype 2–containing oral poliovirus vaccine use, serotype 2 poliovirus outbreaks may still occur and require outbreak response supplemental immunization activities (oSIAs).
Kimberly M. Thompson ScD, Kimberly M. Thompson, Radboud J. Duintjer Tebbens PhD, Radboud J. Duintjer Tebbens   +3 more
core   +1 more source

Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. [PDF]

, 2015
The polio eradication endgame aims to bring transmission of all polioviruses to a halt. To achieve this aim, it is essential to block viral replication in individuals via induction of a robust mucosal immune response. Although it has long been recognized
Parker, EP, Molodecky, NA, Grassly, NC, Parker, Edward Pk, Edward PK Parker, Nicholas C Grassly, O'Reilly, KM, Margarita Pons-Salort, Grassly, Nicholas C, Pons-Salort, Margarita, Molodecky, Natalie A, Kathleen M O’Reilly, Natalie A Molodecky, Pons-Salort, M, O'Reilly, Kathleen M   +14 more
core   +1 more source

Biologicals [PDF]

According to manufacturers, inactivated poliovirus vaccines (IPVs) are freeze sensitive and require storage between 2\ub0C and 8\ub0C, whereas oral poliovirus vaccine requires storage at -20\u202f\ub0C.

core  

The Immunogenicity of Monovalent Oral Poliovirus Vaccine Type 1 (mOPV1) and Inactivated Poliovirus Vaccine (IPV) in the EPI Schedule of India

Background: In 2016, the Global Polio Eradication Initiative (GPEI) recommended the cessation of using type 2 oral poliovirus vaccine (OPV) and OPV, with countries having to switch from the trivalent to bivalent OPV (bOPV) with the addition of ...
T. Jacob John, Padmasani Venkat Ramanan, Lalitendu Mohanty, Shailesh D. Pawar, Sharad Agarkhedkar, Pradeep Haldar   +5 more
core   +1 more source

Circulating vaccine-derived polioviruses: current state of knowledge

Bulletin of the World Health Organization, 2004
Within the past 4 years, poliomyelitis outbreaks associated with circulating vaccine-derived polioviruses (cVDPVs) have occurred in Hispaniola (2000-01), the Philippines (2001), and Madagascar (2001-02).
Kew Olen M., Wright Peter F., Agol Vadim I., Delpeyroux Francis, Shimizu Hiroyuki, Nathanson Neal, Pallansch Mark A.   +6 more
doaj  

Inactivated Poliovirus Vaccine Booster Reduces the Likelihood of COVID-19 Outcomes in Individuals Primed with Oral Poliovirus Vaccination

Introduction: Prior research explores whether seasonal and childhood vaccines mitigate the risk of SARS-CoV-2 infection. Although there are trials investigating COVID-19 infection in response to the effects of the oral poliovirus vaccine (OPV), there has
Chisom Azodoh, Lilly D. Engineer, Aditi Singh, Robin J. Larson, Yea-Jen Hsu, Erin Jackson-Ward, Brittany A. Comunale   +6 more
core   +1 more source

Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine

, 2018
BACKGROUND. Inactivated poliovirus vaccine (IPV) boosts mucosal immunity in persons previously vaccinated with oral poliovirus vaccine (OPV). We assessed whether fractional-dose IPV (fIPV, 1/5th of full dose) administered intradermally also boosts ...
Yiting Zhang, Gamage, Deepa, Ondrej Mach, Sutter, Roland W., Oberste, M. Steven, Weldon, William C., Zhang, Yiting, Gunasena, Sunethra, Mach, Ondrej, William C Weldon, Roland W Sutter, M Steven Oberste, Palihawadana, Paba, Deepa Gamage, Paba Palihawadana, Sunethra Gunasena   +15 more
core   +1 more source

Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control

, 2013
With the circulation of wild poliovirus (WPV) types 1 and 3 continuing more than a decade after the original goal of eradicating all three types of WPVs by 2000, policymakers consider many immunization options as they strive to stop transmission in the ...
Thompson, Kimberly M., Steve G. Wassilak, Stephen L. Cochi, Duintjer Tebbens, Radboud J., Kimberly M. Thompson, Mark A. Pallansch, Wassilak, Steve G., Jong-Hoon Kim, Pallansch, Mark A., Kim, Jong Hoon, Radboud J. Duintjer Tebbens   +10 more
core   +2 more sources

Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus.

PLoS ONE, 2016
BackgroundThe "gold standard" for assessing mucosal immunity after vaccination with poliovirus vaccines consists in measuring virus excretion in stool after challenge with oral poliovirus vaccine (OPV).
Ayan Dey, Natalie A Molodecky, Harish Verma, Prashant Sharma, Jae Seung Yang, Giulietta Saletti, Mohammad Ahmad, Sunil K Bahl, Thomas F Wierzba, Ranjan K Nandy, Jagadish M Deshpande, Roland W Sutter, Cecil Czerkinsky   +12 more
doaj   +1 more source

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use

, 2018
Background Oral polio vaccine (OPV) containing attenuated serotype 2 polioviruses was globally withdrawn in 2016, and bivalent OPV (bOPV) containing attenuated serotype 1 and 3 polioviruses needs to be withdrawn after the certification of eradication of ...
Lee M. Hampton, Kimberly M. Thompson, Radboud J. Duintjer Tebbens   +2 more
core   +1 more source